Utility of 4,6-dichloro-2-(methylthio)-5-nitropyrimidine. An efficient solid-phase synthesis of olomoucine

Tetrahedron Letters

Volumn 43, Issue 45, 2002, Pages 8071-8073

  Hammarström, Lars G J ^a   Smith, David B ^a   Talamás, Francisco X ^a   Labadie, Sharada S ^a   Krauss, Nancy E ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,6 DICHLORO 2 (METHYLTHIO) 5 NITROPYRIMIDINE; OLOMOUCINE; PHOSPHOTRANSFERASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CYCLIZATION; DRUG SYNTHESIS; METHODOLOGY; SOLID; STEREOCHEMISTRY;

EID: 0037020623     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(02)01953-6     Document Type: Article

References (37)

1. Austin R.E., Okonya J.F., Bond D.R.F., Al-Obeidi F. Tetrahedron Lett. 43:2002;6169.
2. Ding S., Gray N.S., Wu X., Ding Q., Schultz P.G. J. Am. Chem. Soc. 124:2002;1594.
3. Ding S., Gray N.S., Wu X., Ding Q., Schultz P.G. J. Comb. Chem. 4:2002;183.
4. Ding S., Gray N.S., Ding Q., Schultz P.G. Tetrahedron Lett. 42:2001;8750.
5. Ding S., Gray N.S., Ding Q., Schultz P.G. J. Org. Chem. 66:2001;8273.
6. Brill W.K.-D., Riva-Toniolo C., Müller S. Synlett. 7:2001;1097.
7. Brun V., Legraverend M., Grierson D.S. Tetrahedron Lett. 42:2001;8161.
8. Brill W.K.D., Riva-Toniolo C. Tetrahedron Lett. 42:2001;6515.
9. Dorff P.H., Garigipati R.S. Tetrahedron Lett. 42:2001;2771.
10. Brill W.K.-D., Riva-Toniolo C., Müller S. Synlett. 7:2001;1097.
11. Chang Y.-T., Gray N.S., Rosania G.R., Sutherlin D.P., Norman T.C., Sarohia R., Leost M., Meijer L., Schultz P.G. Chem. Biol. 6:1999;361.
12. Gray N.S., Wodicka L., Thunnissen A.-M.W.H., Norman T.C., Kwon S., Espinoza F.H., Morgan D.O., Barnes G., LeClerc S., Meijer L., Kim S.-H., Lockhart D.J., Schultz P.G. Science. 281:1998;533.
13. Gray N.S., Kwon S., Schultz P.G. Tetrahedron Lett. 38:1997;1161.
14. Nugiel D.A., Cornelius L.A.M., Corbett J.W. J.Org. Chem. 62:1997;201.
15. Norman, T. C.; Gray, N. S.; Koh, J. T.; Schultz, P. G. J. Am. Chem. Soc. 1996, 118, 7430
16. (p) Di Lucrezia, R.; Gilbert, I. H.; Floyd, C. D. J. Comb. Chem. 2000, 2, 249. Solution-phase methodologies have also been reported. For two recent examples, see: (purines from polyhalo purines);
17. (q) Bakkestuen, A. K.; Gundersen, L.-L.; Langli, G.; Lui, F.; Nolsoe, J. M. J. Biorg. Med. Chem. Lett. 2000, 10, 1207 and (purines from pyrimidines);
18. (r) Dang, Q.; Brown, B. S.; Erion, M. D. Tetrahedron Lett. 2001, 41, 6559.
19. Syntheses of 4,6-dichloro-2-(methylthio)-5-nitropyrimidine 1: (a) Harnden, M. R.; Hurst, D. T. Aust. J. Chem. 1990, 43, 55; (b) Brown, D. J.; Jacobsen, N. W. J. Chem. Soc. 1965, 3770.
20. Syntheses of 4,6-dichloro-2-(methylthio)-5-nitropyrimidine 1: (a) Harnden, M. R.; Hurst, D. T. Aust. J. Chem. 1990, 43, 55; (b) Brown, D. J.; Jacobsen, N. W. J. Chem. Soc. 1965, 3770.
21. For the original report of olomoucine, see: Parker, C. W.; Entsch, B.; Letham, D. S. Phytochemistry 1986, 25, 303. The term olomoucine was coined in 1994 'for convenience', see: Vesely, J. et al. Eur. J. Biochem. 1994, 224, 771.
22. For the original report of olomoucine, see: Parker, C. W.; Entsch, B.; Letham, D. S. Phytochemistry 1986, 25, 303. The term olomoucine was coined in 1994 'for convenience', see: Vesely, J. et al. Eur. J. Biochem. 1994, 224, 771.
23. For recent syntheses, see Refs. 1i and 1n. For bioactivity of olomoucine and related purines, see: Schow, S. R.; Mackman, R. L.; Blum, C. L.; Brooks, E.; Horsma, A. G.; Joly, A.; Kerwar, S. S.; Lee, G.; Shiffman, D.; Nelson, M. G.; Wang, X.; Wick, M. M.; Zhang, X.; Lum, R. T. Bioorg. Med. Chem. Lett. 1997, 7, 2697.
24. The resin used in this work was purchased from Argonaut technologies, see: http://www.argotech.com.
25. Fivush A.M., Willson T.M. Tetrahedron Lett. 38:1997;7151.
26. Sarantakis D., Bicksler J.J. Tetrahedron Lett. 38:1997;7325.
27. In our optimizations of this step, we found reduced temperatures (<50°C) were necessary to avoid displacement of the unactivated thiomethyl moiety.
28. Lee C.L., Chan K.P., Lam Y., Lee S.Y. Tetrahedron Lett. 42:2001;1167.
29. Scheuerman R.A., Tumelty D. Tetrahedron Lett. 41:2000;6531.
30. Krchnak V., Szabo L., Vagner J. Tetrahedron Lett. 41:2000;2835.
31. Yokum T.S., Alsina J., Barany G. J. Comb. Chem. 2:2000;282.
32. Schwarz M.K., Tumelty D., Gallop M.A. Tetrahedron Lett. 39:1998;8397.
33. Morales G.A., Corbett J.W., DeGrado W.F. J. Org. Chem. 63:1998;1172 See also Ref. 1p .
34. Hari, A.; Miller, B. L. Tetrahedron Lett. 1999, 40, 245. We found it advantageous to add a protic solvent (MeOH) to achieve efficient reduction with our substrate. We also achieved limited success following: Makara, G. M.; Ewing, W.; Ma, Y.; Wintner, E. J. Org. Chem. 2001, 66, 5783. In following the latter work, we found THF/water to be more effective than the reported DCM/water with our substrate.
35. Hari, A.; Miller, B. L. Tetrahedron Lett. 1999, 40, 245. We found it advantageous to add a protic solvent (MeOH) to achieve efficient reduction with our substrate. We also achieved limited success following: Makara, G. M.; Ewing, W.; Ma, Y.; Wintner, E. J. Org. Chem. 2001, 66, 5783. In following the latter work, we found THF/water to be more effective than the reported DCM/water with our substrate.
36. 1H NMR.
37. Further work using pyrimidine 1, including applications to library synthesis, has been completed and will be reported in detail shortly.